Symposium: Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment
The meeting will pull together researchers, public health workers, and activists to define an implementation and research agenda for drug-resistant TB and HIV treatment adherence that is centered on the unique needs of the communities most affected by these synergistic epidemics.
TB researchers, advocates and clinicians in New York––please join Columbia University, ICAP, TAG and the Stony-Wold Herbert Foundation at Columbia University on March 19 for a symposium titled "Re-inventing adherence: Patient-centered approaches to drug-resistant TB and HIV treatment".
Please visit tbhiv-colloq.org for further details and to register for the event. See agenda here.
Drug-resistant TB/HIV is a global health emergency. The
development of new TB diagnostics, drugs and treatment regimens
presents us with exciting opportunities to improve outcomes for
patients and reduce community transmission of drug-resistant TB.
Without equally innovative approaches to
patient-centered care, this opportunity to impact the epidemic
may be short-lived. It is time to re-invent our understanding of
adherence in drug-resistant TB/HIV to eliminate disease and the
stigma associated with it by focusing our efforts and attention
on affected patients and communities.
The meeting
will pull together researchers, public health workers, and
activists to define an implementation and research agenda for
drug-resistant TB and HIV treatment adherence that is centered
on the unique needs of the communities most affected by these
synergistic epidemics.
